Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings

CAMBRIDGE, Mass.--()--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease (CKD), including new pharmacokinetic data, will be presented in a poster presentation at the National Kidney Foundation 2016 Spring Clinical Meetings taking place in Boston from April 27-May 1.

The details of the presentation are as follows:

Date and Time: April 28, 2016 from 6:00 – 7:30 pm EDT

Poster Title: Vadadustat – a Novel, Oral Treatment for Anemia of CKD -- Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimulating Agent (ESA)

Poster Number: 171

The poster will be available after the presentation at http://akebia.com/media/.

About Vadadustat

Vadadustat is an oral therapy currently in development for the treatment of anemia related to CKD. Vadadustat is designed to stabilize HIF, a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to changes in oxygen levels, by inhibiting the hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzyme. Vadadustat exploits the same mechanism of action used by the body to naturally adapt to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin (EPO) production to increase RBC production and, ultimately, improve oxygen delivery.

As a HIF stabilizer with best-in-class potential, vadadustat raises hemoglobin levels predictably and sustainably, with a dosing regimen that allows for a gradual and controlled titration. Vadadustat has been shown to improve iron mobilization, potentially eliminating the need for intravenous iron administration and reducing the overall need for iron supplementation.

About Anemia Related to CKD

Approximately 30 million people in the United States have CKD, with an estimated 1.8 million of these patients suffering from anemia. Anemia results from the body's inability to coordinate RBC production in response to lower oxygen levels due to the progressive loss of kidney function, which occurs in patients with CKD. Left untreated, anemia significantly accelerates patients' overall deterioration of health with increased morbidity and mortality. Renal anemia is currently treated with injectable recombinant ESAs, which are associated with inconsistent hemoglobin responses and well-documented safety risks.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT Phase 3 program in non-dialysis commenced in late 2015 and the INNO2VATE Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016. For more information, please visit our website at www.akebia.com.

Contacts

Argot Partners for Akebia Therapeutics
Investors:
Susan Kim, +1-212-600-1902
Susan@argotpartners.com
or
Media:
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com

Recent Stories

RSS feed for Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.